This site is intended for healthcare professionals

AZD 7442 reduced risk of developing severe COVID-19 or death in TACKLE phase III outpatient treatment trial.

Read time: 1 mins
Last updated:11th Oct 2021
Published:11th Oct 2021
Positive high-level results from the TACKLE Phase III COVID-19 treatment trial showed AstraZeneca's AZD 7442, a long acting antibody (LAAB) combination (tixagevimab + cilgavimab), achieved a statistically significant reduction in severe COVID-19 or death compared to placebo in non-hospitalised patients with mild-to-moderate symptomatic COVID-19.
Condition: Coronavirus/COVID-19 Infection
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights